17th EFMC Short Course on Medicinal Chemistry
Small Molecule Protein Degraders: A New Opportunity for Drug Design and Development

Course Outline:
In the last ten years there have been significant developments in the field of designing small molecule protein degraders both as chemical tools and clinical candidates. These degraders can offer major advantages over small molecule inhibitors as a therapeutic strategy by achieving more complete target inhibition and by expanding the potentially druggable proteome. This course aims to provide opportunities for in depth discussions on the key aspects of PROTAC design and development for medicinal chemists. The course will introduce small molecule protein degraders, including PROTACs and molecular glues, and give a detailed overview of the novel technologies used to characterise protein degradation biophysically and in living cells. The course will finish with a series of medicinal chemistry case studies, including the discovery of clinical small molecule protein degraders.
Confirmed Speakers:
The Ternary Complex E3-Degrader-Target: Biophysical Binding Assays and Structures
- Dr Chun-wa Chung (GSK, United Kingdom)
Introduction to Small Molecule Degraders: PROTACS and Molecular Glues
- Prof. Alessio Ciulli (University of Dundee, United Kingdom)
- Dr Suzanne O'Connor (University of Dundee, United Kingdom)
Importance of Degradation Kinetics and Mechanisms for Development of Potent Therapeutic Degraders
- Dr Danette Daniels (Foghorn Therapeutics, United States)
The Current & Future Clinical Landscape of Molecular Degraders of Disease-Causing Proteins
- Dr Ingo Hartung
Medicinal Chemistry Optimisation of Small Molecule Degraders
- Dr Andrea Testa
Course Organisers:
- Prof. Alessio Ciulli (University of Dundee, United Kingdom)
- Prof. Suzanne O'Connor (University of Dundee, United Kingdom)
Local Organiser:
- Prof. Laura Heitman (Leiden University, The Netherlands)
16th EFMC Short Course on Medicinal Chemistry
New Opportunities in GPCR Drug Discovery

Due to the exceptional circumstances faced with the coronavirus pandemic (COVID-19), the 16th EFMC Short Course on Medicinal Chemistry has been postponed to May 8-11, 2022. Registrations will open soon!
************************************************************
This intensive course is intended for scientists working in the field, and the presentations will be given by senior scientists from industry and academia. The number of participants is limited to 35, to allow in depth discussion. Should the number of applications exceed the maximum, preference will be given to applicants from EFMC adhering countries and employees of EFMC corporate members. Upon special request to the organisers, only based on financial conditions and supported by an argued recommendation of the head of the department of the applicant, up to 3 applicants from academia may be admitted at a reduced fee.
Course Outline
G-protein coupled receptors represent the largest class of drug targets. Although they serve as targets for about 30% of the known drugs, many of them is still orphan. In the last 15 years, however, we witnessed dramatic developments in the structural biology and pharmacology of GPCRs. High resolution X-ray and cryo-EM structures made the design of the GPCR ligands more rational. The widening knowledge on their signalling resulted in new concepts such as allosteric modulation, GPCR residence time and biased signalling currently tested in clinical trials. This course will provide an introduction for medicinal chemists to this important target class including concepts and methods applied in the structural biology, modelling, systems biology, pharmacology and medicinal chemistry of GPCRs. The course will finish with a series of medicinal chemistry case studies, including the discovery of molecular probes, tool compounds, clinical candidates and marketed drugs.
Course Organisers
György Miklós KESERÜ (Research Centre for Natural Sciences, Hungarian Academy of Sciences, Hungary)
Rob LEURS (VU University Amsterdam, The Netherlands)
Local Organisers
Henk TIMMERMAN (VU University Amsterdam, The Netherlands)
Laura HEITMAN (University of Leiden, The Netherlands)
15th EFMC Short Course on Medicinal Chemistry - Small Becomes Big in Medicinal Chemistry: Fragment-based Drug Discovery
This intensive course is intended for scientists working in the field, and the presentations will be given by senior scientists from industry and academia. The number of participants is limited to 35, to allow in depth discussion. Should the number of applications exceed the maximum, preference will be given to applicants from EFMC adhering countries and employees of EFMC corporate members. Upon special request to the organisers, only based on financial conditions and supported by an argued recommendation of the head of the department of the applicant, up to 3 applicants from academia may be admitted at a reduced fee.
Confirmed Speakers:
- Dr Xavier BARRIL (GAIN THERAPEUTICS, Mataro)
- Dr Ben DAVIS (VERNALIS PLC, Cambridge, United Kingdom)
- Dr Paul ENGLAND (IOTA PHARMACEUTICALS LTD., Cambridge, United Kingdom)
- Dr Mike HANN (GLAXOSMITHKLINE, Stevenage, United Kingdom)
- Prof. Rod HUBBARD (UNIVERSITY OF YORK & VERNALIS, Cambridge, United Kingdom)
- Prof. Gyorgy KESERU (RESEARCH CENTRE FOR NATURAL SCIENCES, HUNGARIAN ACADEMY OF SCIENCES, Budapest, Hungary)
Organised by: Iwan DE ESCH (VU University Amsterdam, The Netherlands) and Henk TIMMERMAN (VU University Amsterdam, The Netherlands)
- European Federation for Medicinal Chemistry and Chemical Biology (EFMC)
14th EFMC Short Course on Medicinal Chemistry - Peptide Therapeutics: Inspiring Beacon of Hope for the Pharmaceutical Future
Organised by Bart De Spiegeleer and Henk Timmerman
13th EFMC Short Course on Medicinal Chemistry - A Matter of Time; A Kinetic Perspective on Drug-Target Interactions
In this EFMC short course, experts in the field will provide a firm conceptual framework for the study of target binding kinetics. Tutorials and real life examples will assist the participants in the short course to grasp not only a basic understanding but also to bring home inspiring case studies from both an academic and industrial perspective. The number of participants will be limited to 35 to assure interactive and in-depth discussions.
Organised by Ad Ijzerman, Laura Heitman and Henk Timmerman
Confirmed Speakers
- Prof. Helena DANIELSON (UPPSALA UNIVERSITY, Uppsala, Sweden)
- Dr Liesbeth DE LANGE (UNIVERSITY OF LEIDEN, Leiden, The Netherlands)
- Dr Wilbert DE WITTE (UNIVERSITY OF LEIDEN, Leiden, The Netherlands)
- Dr Matthias FRECH (MERCK, Darmstadt, Germany)
- Dr Laura HEITMAN (UNIVERSITY OF LEIDEN, Leiden, The Netherlands)
- Prof. Ad P. IJZERMAN (UNIVERSITY OF LEIDEN, Leiden, The Netherlands)
- Prof. Georges VAUQUELIN (VUB, Brussel, Belgium)
12th EFMC Short Course on Medicinal Chemistry - Modulation of Enzymes; Epigenetics and Beyond
In 2009, EFMC launched a series of short courses aimed to favour cultural and scientific growth of the medicinal chemistry community and organised with affordable fees for participation.
This intensive course is intended for scientists working in the field, and the presentations will be given by senior scientists from industry and academia. The number of participants will be limited to 35, to favour in depth discussion. Should the number of applications exceed the maximum, preference will be given to applicants from EFMC adhering countries and employees of EFMC corporate members. Upon special request to the organisers, only based on financial conditions and supported by an argued recommendation of the head of the department of the applicant, a limited number of applicants from academia (maximum 3) may be admitted at a reduced fee.
Speakers
- The PDE Family and Inhibitors
Dr Andrew BELL (Iperial College London, United Kingdom) - Epigenetic Target Families in Medicinal Chemistry
Prof. Paul BRENNAN (University of Oxford, United Kingdom) - Brodomain Inhibitors - from Phenotypic Screens to Fragments
Dr Chun-wa CHUNG (Glaxosmithkline R&D, United Kingdom) - Fragment-Based Lead Generation
Prof. Iwan DE ESCH (VU University Amsterdam, The Netherlands) - Glycomimetics - an Underexplored Compound Class for Medicinal Chemistry
Prof. Dr Beat ERNST (University of Basel, Switzerland) - Proteasome Inhibitors
Prof. Michael GROLL (Technische Universität Munchen, Germany) - Basic Principles of Enzymology
Dr Laurie LEBRUN (Celgene, United States) - Kinases and Inhibitors
Dr Gerhard MÜLLER (Mercachem, The Netherlands) - The Protease Target Family
Dr Holger SELLNER (Novartis, Switzerland) - Parallel Hands on Tutorials - Cases Study I
Dr Leon VAN BERKOM (Mercachem, The Netherlands)
Dr Toine VAN DEN BERGH (Mercachem, The Netherlands) - Parallel Hands on Tutorials - Cases Study II
Dr Stijn GREMMEN (Mercachem, The Netherlands)
Dr Harald ALBERS (Mercachem, The Netherlands)
Course outline
Enzymes encompass a vast number of distinct target families relevant for contemporary medicinal chemists‘ endeavor to the discovery of efficient and safe drugs. A recent analysis of about 1.000 drugs approved from 1982 – 2010 uncovered around 450 effect-mediating drug targets of which only 150 cluster into enzyme families. However, the ratio of enzyme inhibitors among all approved drugs has increased over the last 10 years; of all ‘true NCEs’ that reached the market from 2005 onwards, more than 50% exert their therapeutic effect by modulation of human and pathogenic enzymes. Many of the approved inhibitors modulate enzymes that cluster into densely populated target families that will be scrutinized in the 12th EFMC Short Course on Medicinal Chemistry. Hence, the focus of this course will be centered on all aspects of enzyme inhibitor discovery addressing the widely unexploited potential of both, the established enzyme classes such as proteases and kinases, as well as the modern emerging enzyme families from e.g. the epigenetics area. A collection of renowned international experts in the field will highlight various methodological, technological, and enzymological aspects of medicinal chemistry aimed at the discovery of inhibitors against proteases, kinases, phosphodiesterases, as well as epigenetic targets, respectively. Lectures and discussions will be complemented by interactive hands-on sessions on selected case studies in which the participants will be challenged to pursue hit-to-lead and subsequent lead optimization campaigns, supervised by experienced medicinal chemists.
Course Organisers
Gerhard Müller (Mercachem, The Netherlands)
Anita Wegert (Mercachem, The Netherlands)
Local Organiser
Henk TIMMERMAN (VU University Amsterdam, The Netherlands)
11th EFMC Short Course on Medicinal Chemistry - Engineering of Biopharmaceuticals - Cancelled
Organised by Jesper Lau and Henk Timmerman
10th EFMC Short Course on Medicinal Chemistry - Small-Molecule Modulation of Protein-Protein Interactions (PPIs)
Organised by Luc Brunsveld, Christian Ottman and Henk Timmerman
9th EFMC Short Course on Medicinal Chemistry - Principles of Molecular Recognition
Organised by George Keseru, Andrew Leach and Henk Timmerman
8th EFMC Short Course on Medicinal Chemistry - Engineering of Biopharmaceuticals
Organised by Jesper Lau and Henk Timmerman
7th EFMC Short Course on Medicinal Chemistry - Principles of Molecular Recognition
Organised by George Keseru and Henk Timmerman
6th EFMC Short Course on Medicinal Chemistry - Improving Compound Quality: Physical Chemistry and DMPK Properties in Drug Discovery. Principles, Assays and Predictions
Organised by Kevin Beaumont and Henk Timmerman
5th EFMC Short Course on Medicinal Chemistry - Target Selection through Application of Chemical and Systems Biology
Organised by Thomas Klabunde, Brian Harms and Henk Timmerman
4th EFMC Short Course on Medicinal Chemistry - Safety and Attrition
Organised by Alan Stobie and Henk Timmerman
3rd EFMC Short Course on Medicinal Chemistry - Principles and Applications of in vitro Pharmacology in Drug Discovery for Medicinal Chemists
Organised by Mike Trevethick and Henk Timmerman
2nd EFMC Short Course on Medicinal Chemistry - Safety and Attrition
Organised by Alan Stobie and Henk Timmerman
1st EFMC Short Course on Medicinal Chemistry - Improving Compound Quality
Organised by Han van den Waterbeemd and Henk Timmerman